Relationship between arm morbidity and patient-reported outcomes following surgery in women with node-negative breast cancer: NSABP protocol B-32

Journal of Supportive Oncology

Volumn 11, Issue 1, 2013, Pages 22-30

  Kopec, Jacek A ^a,b   Colangelo, Linda H ^a,c   Land, Stephanie R ^a,c   Julian, Thomas B ^a,d   Brown, Ann M ^a,c   Anderson, Stewart J ^a,c   Krag, David N ^a,e,f   Ashikaga, Takamaru ^f   Costatino, Joseph P ^a,c   Wolmark, Norman ^a,d   Ganz, Patricia A ^a,g  

^a NSABP Foundation Inc   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d ALLEGHENY GENERAL HOSPITAL   (United States)

^e FLETCHER ALLEN HEALTH CARE   (United States)

^f UNIVERSITY OF VERMONT   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARM EDEMA; ARM MOVEMENT; ARM PAIN; ARM WEAKNESS; ARTICLE; BREAST CANCER; BREAST SURGERY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HAND PARESTHESIA; HUMAN; IMMOBILITY; LYMPH NODE DISSECTION; LYMPHEDEMA; MAJOR CLINICAL STUDY; OCCUPATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RANGE OF MOTION; RECREATION; SENSORY NEUROPATHY; SKIN TINGLING; SOCIAL BEHAVIOR; TREATMENT OUTCOME; WORK CAPACITY; ARM; BREAST TUMOR; CONTROLLED CLINICAL TRIAL; DAILY LIFE ACTIVITY; FOLLOW UP; JOINT CHARACTERISTICS AND FUNCTIONS; MASTECTOMY; MIDDLE AGED; MORBIDITY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PATIENT PARTICIPATION; POSTOPERATIVE COMPLICATION; PROGNOSIS; SELF REPORT; UTILIZATION REVIEW;

ACTIVITIES OF DAILY LIVING; ARM; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHEDEMA; MASTECTOMY; MIDDLE AGED; MORBIDITY; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT PARTICIPATION; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; QUALITY OF LIFE; RANGE OF MOTION, ARTICULAR; SELF REPORT;

MLCS; MLOWN;

EID: 84879333822     PISSN: 15446794     EISSN: 1879596X     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Hack TF, Cohen L, Katz J, Robson LS, Goss P. Physical and psychological morbidity after axillary lymph node dissection for breast cancer. J Clin Oncol. 1999;17(1):143-149.
2. Ahmed RL, Prizment A, Lazovich DA, Schmitz KH, Folsom AR. Lymphedema and quality of life in breast cancer survivors: the Iowa Women's Health Study. J Clin Oncol. 2008;26(35):5689-5696.
3. Rietman JS, Dijkstra PU, Debreczeni R, Geertzen JH, Robinson DP, DeVries J. Impairments, disabilities and health related quality of life after treatment for breast cancer: a follow-up study 2.7 years after surgery. Disabil Rehabil. 2004;26(2):78-84.
4. Nesvold IL, Fosså SD, Holm I, Naume B, Dahl AA. Arm/shoulder problems in breast cancer survivors are associated with reduced health and poorer physical quality of life. Acta Oncol. 2010;49(3): 347-353.
5. Hormes JM, Bryan C, Lytle LA, et al. Impact of lymphedema and arm symptoms on quality of life in breast cancer survivors. Lymphology. 2010;43(1):1-13.
6. Kaya T, Karatepe AG, Günaydn R, Yetiş H, Uslu A. Disability and health-related quality of life after breast cancer surgery: relation to impairments. South Med J. 2010;103(1):37-41.
7. Edge SB, Niland JC, Bookman MA, et al. Emergence of sentinel node biopsy in breast cancer as standard of care in academic comprehensive cancer centers. J Natl Cancer Inst. 2003;95(20):1514-1521.
8. Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23(30): 7703-7720.
9. Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial [published correction appears in J Natl Cancer Inst. 2006;98(12):876]. J Natl Cancer Inst. 2006;98(9):599-609.
10. Fleissig A, Fallowfield LJ, Langridge CI, et al. Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res Treat. 2006;95(3):279-293.
11. Zavagno G, De Salvo GL, Scalco G, et al. A randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial. Ann Surg. 2008;247(2):207-213.
12. Gill G; SNAC Trial Group of the Royal Australasian College of Surgeons (RACS) and NHMRC Clinical Trials Centre. Sentinel lymph node-based management or routine axillary clearance? Oneyear outcomes of sentinel node biopsy versus axillary clearance (SNAC): a randomized controlled surgical trial. Ann Surg Oncol. 2009;16(2):266-275.
13. Land SR, Kopec JA, Julian TB, et al. Patient-reported outcomes in sentinel node-negative adjuvant breast cancer patients receiving sentinel-node biopsy or axillary dissection: National Surgical Adjuvant Breast and Bowel Project phase III protocol B-32 [published correction appears in J Clin Oncol. 2010;28(36):5350]. J Clin Oncol. 2010;28(25):3929-3936.
14. Ashikaga T, Krag DN, Land SR, et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol. 2010;102(2):111-118.
15. Veronesi U, Paganelli G, Viale G, et al. Sentinel lymph node biopsy as a staging procedure in breast cancer: Update of a randomised controlled study. Lancet Oncol. 2006;7(12):983-990.
16. Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349(6):546-553.
17. Purushotham AD, Upponi S, Klevesath MB, et al. Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. J Clin Oncol. 2005;23(19):4312-4321.
18. Schrenk P, Rieger R, Shamiyeh A, Wayand W. Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma. Cancer. 2000;88(3):608-614.
19. Haid A, Kuehn T, Konstantiniuk P, et al. Shoulder-arm morbidity following axillary dissection and sentinel node only biopsy for breast cancer. Eur J Surg Oncol. 2002;28(7):705-710.
20. Burak WE, Hollenbeck ST, Zervos EE, Hock KL, Kemp LC, Young DC. Sentinel lymph node biopsy results in less postoperative morbidity compared with axillary lymph node dissection for breast cancer. Am J Surg. 2002;183(1):23-27.
21. Rietman JS, Dijkstra PU, Geertzen JH, et al. Treatment-related upper limb morbidity 1 year after sentinel lymph node biopsy or axillary lymph node dissection for stage I or II breast cancer. Ann Surg Oncol. 2004;11(11):1018-1024.
22. Langer I, Guller U, Berclaz G, et al. Morbidity of sentinel lymph node biopsy (SLN) alone versus SLN and completion axillary lymph node dissection after breast cancer surgery: a prospective Swiss multicenter study on 659 patients. Ann Surg. 2007;245(3): 452-461.
23. Husted Madsen A, Haugaard K, Soerensen J, et al. Arm morbidity following sentinel lymph node biopsy or axillary lymph node dissection: a study from the Danish Breast Cancer Cooperative Group. Breast. 2008;17(2):138-147.
24. Krag DN, Anderson SJ, Julian TB, et al. Technical outcomes of sentinel lymph node resection and conventional axillary lymph node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol, 2007;8(10):881-888.
25. Krag DN, Anderson SJ, Julian TB, et al. Sentinel lymph node resection compared with conventional axillary lymph node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11(10):927-933.
26. Muir SW, Corea CL, Beaupre L. Evaluating change in clinical status: reliability and measures of agreement for the assessment of glenohumeral range of motion. N Am J Sports Phys Ther. 2010;5(3): 98-110.
27. Taylor R, Jayasinghe UW, Koelmeyer L, Ung O, Boyages J. Reliability and validity of arm volume measurements for assessment of lymphedema. Phys Ther. 2006;86(2):205-214.
28. Ganz PA, Coscarelli A, Fred C, Kahn B, Polinsky ML, Petersen L. Breast cancer survivors: psychosocial concerns and quality of life. Breast Cancer Res Treat. 1996;38(2):183-199.
29. Hudak PL, Amadio PC, Bombardier C. Development of an upper extremity outcome measure: the DASH (disabilities of the arm, shoulder and hand) [published correction appears in Am J Ind Med. 1996;30(3):372]: The Upper Extremity Collaborative Group (UECG). Am J Ind Med. 1996;29(6):602-608.
30. Shimozuma K, Ganz PA, Petersen L, Hirji K. Quality of life in the first year after breast cancer surgery: rehabilitation needs and patterns of recovery. Breast Cancer Res Treat. 1999;56(1):45-57.
31. Westrup JL, Lash TL, Thwin SS, Silliman RA. Risk of decline in upper-body function and symptoms among older breast cancer patients. J Gen Intern Med. 2006;21(4):327-333.
32. Kopec JA, Yothers G, Ganz PA, et al. Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06 [published correction appears in J Clin Oncol. 2007;25(34):5540-5541]. J Clin Oncol. 2007;25(4): 424-430.
33. Land SR, Kopec JA, Yothers G, et al. Health-related quality of life in axillary node-negative, estrogen receptor-negative breast cancer patients undergoing AC versus CMF chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel Project B-23. Breast Cancer Res Treat. 2004;86(2):153-164.
34. de Boer AG, van Lanschot JJ, Stalmeier PF, et al. Is a single-item visual analogue scale as valid, reliable and responsive as multi-item scales in measuring quality of life? Qual Life Res. 2004;13(2):311-320.
35. Farivar SS, Liu H, Hays RD. Half standard deviation estimate of the minimally important difference in HRQOL scores? Expert Rev Pharmacoecon Outcomes Res. 2004;4(5):515-523.
36. Torrance GW, Feeny D, Furlong W. Visual analog scales: do they have a role in the measurement of preferences for health states? Med Decis Making. 2001;21(4):329-334.